Medicus Pharma's CEO and leadership team met with US Congress members to seek support for regulatory approval and orphan drug designation for SkinJect, a therapy targeting Gorlin syndrome, a rare genetic condition causing recurrent skin cancers. The company aims to advance SkinJect as a non-surgical treatment alternative to repeated surgeries for basal cell carcinomas common in these patients. Discussions included support for the FDA's rare pediatric disease voucher program to accelerate development. Medicus Pharma is continuing clinical and regulatory planning to expedite SkinJect's approval for this underserved patient group.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
